Daily Health Headlines

2nd Baby 'Cured' of HIV Suffers Relapse

👤by Dennis Thompson 0 comments 🕔Friday, October 3rd, 2014

THURSDAY, Oct. 2, 2014 (HealthDay News) -- An Italian toddler thought cured of HIV with early aggressive treatment following birth has suffered a relapse, his doctors report.

The 3-year-old child's viral levels of HIV rebounded two weeks after doctors took him off antiretroviral medications, according to a case report published Oct. 4 in The Lancet.

The child's HIV levels had been undetectable since he was 6 months old, thanks to aggressive drug therapy that doctors started within 12 hours of his birth, doctors said.

This is the second time that a child believed "cured" of HIV with early treatment has suffered a relapse once they stopped taking antiretroviral medication.

In July, a 4-year-old Mississippi girl relapsed after living HIV-free for more than two years without medication.

"What we've learned here is if you have an HIV-infected child who started treatment early, the fact that you have negative tests does not signify that the child has been cured or that they can be taken off treatment," said Dr. Deborah Persaud. She is a professor of infectious diseases at the John Hopkins Children's Center in Baltimore and one of the two pediatric HIV experts involved in the ongoing analysis of the Mississippi case.

The Italian boy, known as the "Milan baby," was born to an HIV-positive mother in December 2009.

He was born with a heavy HIV viral load, and doctors immediately put him on antiretroviral therapy. His HIV levels immediately began to drop, and were undetectable at 6 months of age.

Tests at age 3 to measure the amount of HIV in the child's blood suggested that the virus had been eradicated, and even antibodies to HIV had disappeared. With the agreement of the child's mother, doctors took him off his medication regimen.

Unfortunately, the virus had been hiding in reservoirs deep in the child's immune system, and immediately rebounded, the researchers said.

The cases highlight the difficulty of eliminating HIV from deep within the immune system.

The virus infects the "memory cells" of the immune system -- cells that lie dormant deep within the system and retain the knowledge of how to respond to different types of infection, Persaud said. These cells wait in reserve, ready to be called upon to fight off a future illness.

Because these cells are dormant, drug treatments that rid the bloodstream of HIV are not able to get inside them and kill off the virus hiding within, she explained. And once antiretroviral treatment stops, any immune response that activates these memory cells will cause the patient's HIV to re-emerge.

"It takes advantage of the very biology we use to cope with infections," said Dr. Bruce Hirsch, an infectious diseases specialist at North Shore University Hospital in Manhasset, N.Y.

Despite these setbacks, doctors have not given up on a "functional cure" for children born with HIV.

Hirsch noted that HIV therapy given to an infected mother prior to birth has been shown to prevent transmission of the virus to her newborn.

"Because of that, I think it's possible there may be some potential to prevent HIV infection in the first place after exposure with early therapies," he said.

A clinical trial is moving forward to examine treatment of HIV-positive babies within the first 48 hours of life, using a drug combination similar to that administered to the Mississippi baby, Persaud said.

Dr. Michael Horberg, director of HIV/AIDS for Kaiser Permanente, agreed there is still merit to the strategy of aggressive early treatment for HIV-born infants.

"I think we will find a functional cure. We just haven't found it yet," Horberg said. "That doesn't mean the principles of a strategy of hitting hard for an extended period should not work."

At the same time, doctors should not become too hung up on the promise of a cure, when current drug therapies are as successful at controlling HIV infection as blood pressure medications are at controlling blood pressure, Hirsch said.

"Our treatments are very well-tolerated, and I think we should avoid cures that are worse than the treated disease itself," he said.

Article Credits / Source

Dennis Thompson / HealthDay

Dennis Thompson wrote this story for HealthDay. HealthDay provides up to the minute breaking health news. Click here to view this full article from HealthDay.

SOURCES: Deborah Persaud, M.D., professor, infectious diseases, John Hopkins Children's Center, Baltimore; Bruce Hirsch, M.D., infectious diseases specialist, North Shore University Hospital, Manhasset, N.Y.; Michael Horberg, M.D., director, HIV/AIDS, Kaiser Permanente; Oct. 4, 2014, The Lancet

View More Articles From Dennis Thompson 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More HIV Articles

Drug Combo Shows Early Promise for Remission of HIV

Drug Combo Shows Early Promise for Remission of HIV0

THURSDAY, Nov. 10, 2016 (HealthDay News) -- Animal research with an experimental two-drug therapy could hold clues for creating long-term HIV remission in people living with the virus, a new report says. The goal: to free patients from the need ...

Antibodies May Hold Key to HIV Suppression

Antibodies May Hold Key to HIV Suppression0

WEDNESDAY, Nov. 9, 2016 (HealthDay News) -- Antibodies may keep the HIV virus in check and one day let patients stop taking antiretroviral drugs, two new preliminary trials suggest. Researchers tried to quell HIV in 23 patients with infusions ...

Experimental Medicine Might Rescue People With Drug-Resistant HIV

Experimental Medicine Might Rescue People With Drug-Resistant HIV0

FRIDAY, Oct. 28, 2016 (HealthDay News) -- Researchers report that a new medication might revolutionize the treatment of HIV patients who don't respond to existing drugs. The intravenous drug, known as ibalizumab, is given every two weeks. It's ...

Study Discounts Myth of 'Patient Zero' in U.S. AIDS Crisis

Study Discounts Myth of 'Patient Zero' in U.S. AIDS Crisis0

WEDNESDAY, Oct. 26, 2016 (HealthDay News) -- Using genetic analyses of 40-year-old blood samples, scientists have arrived at a clearer understanding of the introduction and spread in North America of the virus that causes AIDS. One myth already ...

HIV May Hide in Tissues, Even After Treatment

HIV May Hide in Tissues, Even After Treatment0

WEDNESDAY, Oct. 26, 2016 (HealthDay News) -- HIV patients who've been treated with antiretroviral drugs still have the AIDS-causing virus in their tissues, a new study suggests. Treatment with antiretrovirals eliminates detectable levels of HIV ...

View More HIV Articles


Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!